Glenmark Pharmaceuticals launches Tavulus for COPD treatment in Spain
Since its launch, they have seen the multiple therapeutic benefits of Tavulus® in other markets, and are pleased to extend these benefits to patients in Spain.
Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company today announced the launch of a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name Tavulus® in Spain, for the treatment of chronic obstructive pulmonary disease (COPD).
COPD is a long-term condition that causes inflammation in the lungs, damaging the lung tissue and narrowing the airways, all of which make breathing difficult. Studies show that close to 2.5 million people suffer from COPD in Spain.
Tavulus® is expected to provide relief to a large patient population in the country. It is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs. It also works to prevent sudden, short-term worsening of COPD symptoms.
Commenting on the launch, Vice President - Business Development of Glenmark Pharmaceuticals Limited, Jiří Havránek, says, "The goal of COPD treatment has always been to provide quick symptomatic relief to patients and reduce the risk of exacerbations. Since its launch, they have seen the multiple therapeutic benefits of Tavulus® in other markets, and they are pleased to extend these benefits to patients in Spain. This inhalation therapy has been shown to significantly aid in the daily management of COPD. They hope that it improves both COPD symptoms and quality of life in those who are most affected."
Future Plans
Glenmark is planning subsequent launches of the product across these markets under the brand name Tiogiva® in UK, Ireland, Sweden, Finland and Norway; Tavulus® in Denmark and Netherlands; and Tiotropium Glenmark® in Germany.
Key Points
- Tiotropium DPI had a market size of US$ 433 Mn in the EU in the 12-month period ended March 2021 (IQVIA data)
- Tavulus® is Glenmark’s bioequivalent version of Boehringer Ingelheim’s Spiriva® Handihaler®
- The launch is part of a wider Glenmark’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK.
Glenmark Pharmaceuticals Limited (Glenmark) is a global research-led pharmaceutical company with presence across generics, specialty and OTC businesses and with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology
At the closing bell on Monday, the stock was trading at Rs. 534.35, up by 1.36% per cent for the day.